This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Trifarotene topical


Topical formulation of trifarotene.

Drugs List

  • AKLIEF 50microgram/g cream
  • trifarotene 50microgram/g cream
  • Therapeutic Indications


    Acne vulgaris

    Treatment of Acne Vulgaris of the face and/or trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present.



    One application to the affected area in the evening, on clean and dry skin.

    The physician should assess the continued improvement of the patient after 3 months of treatment.


    Children under 12 years

    Precautions and Warnings

    Females of childbearing potential
    Patients over 65 years
    Hepatic impairment
    Renal impairment

    Contains propylene glycol: may cause irritation
    Advise patient to wash hands after use
    Avoid administration to eczematous or inflamed skin
    Avoid application to broken skin
    Avoid contact with eyes, lips or mouth
    Avoid contact with mucous membranes
    Review treatment after 3 months then periodically thereafter
    Discontinue if burning sensation occurs
    Discontinue if sensitisation occurs
    Pregnancy confirmed: Discontinue this medication
    Reduce application frequency/temporarily discontinue if irritation occurs
    Advise patient that the use of topical moisturisers may be necessary
    Advise patient to avoid exposure to sunlight and UV rays during treatment

    Use of 'waxing' as a depilatory method should be avoided on skin treated with trifarotene.

    Caution should be exercised if cosmetics or acne medications with desquamative, irritant or drying effects are concomitantly used with trifarotene, as they may produce additive irritant effects.

    Pregnancy and Lactation


    Trifarotene is contraindicated during pregnancy.

    Use of trifarotene during pregnancy is contraindicated by the manufacturer. Animal studies with trifarotene by the oral route have shown reproductive toxicity at high systemic exposure. If the patient is pregnant or becomes pregnant while taking this drug, treatment should be discontinued.


    Trifarotene is contraindicated during breastfeeding.

    The manufacturer recommends that a decision must be made whether to discontinue breastfeeding or to discontinue trifarotene treatment taking into account the benefit of breastfeeding for the child and the benefit of treatment for the woman. It is unknown whether trifarotene or its metabolites are excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of trifarotene in milk. Effects on exposed infants are unknown.

    To avoid the risk of ingestion by, and/or contact exposure of, an infant, nursing women should not apply trifarotene cream to the chest or breast area.


    Advise patient to avoid contact with the eyes, eyelids, lips and mucous membranes and to wash their hands after applying trifarotene.

    Side Effects

    Allergic dermatitis
    Asteatotic eczema
    Burning sensation (local)
    Dry skin
    Erythema at application site
    Eyelid exfoliation
    Eyelid oedema
    Hyperpigmentation of skin
    Irritation at application site
    Localised urticaria
    Pain at application site
    Scaling of skin
    Seborrhoeic dermatitis
    Skin discolouration
    Skin fissures
    Skin irritation
    Stinging (transient)


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: July 2022

    Reference Sources

    Summary of Product Characteristics: Aklief 50 microgram/g cream. Galderma (U.K) Ltd. Revised December 2020.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.